Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Jing Li

14PUBLICATIONS

74CO-AUTHORS

Molecular targetsMedical infection agents (incl. prions)Genome structure and regulationCancer therapy (excl. chemotherapy and radiation therapy)Powder and particle technology

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (14)

Sort by Publication Date:

|Mar 24, 2026

The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancer.

Jiani Zheng, Shen Zhao, Jianhua Zhan

|Nov 01, 2025

A special latch in yeast mitofusin guarantees mitochondrial fusion by stabilizing self-assembly.

Shu-Jing Huang, Dong-Fei Ma, Caiting Yu

|Apr 15, 2025

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib.

Yihua Huang, Jie Huang, Jianhua Zhan

|Oct 29, 2024

ScRAPdb: an integrated pan-omics database for the Saccharomyces cerevisiae reference assembly panel.

Zepu Miao, Yifan Ren, Andrea Tarabini

|Apr 10, 2024

Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.

Yaxiong Zhang, Zihong Chen, Yu Liu

|Apr 05, 2024

Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.

Lanlan Pang, Yihua Huang, Weitao Zhuang

Pageof 3

Frequent Collaborators

7 joint publications

Jia-Xing Yue

5 joint publications

Gianni Liti

2 joint publications

Feng Hao

2 joint publications

Huihui Li

2 joint publications

Weitao Zhuang

2 joint publications

Shujing Huang

2 joint publications

Yihua Huang

2 joint publications

Song Gao

2 joint publications

Zepu Miao

2 joint publications

Gilles Fischer

Frequent Collaborators

7 joint publications

Jia-Xing Yue

5 joint publications

Gianni Liti

2 joint publications

Feng Hao

2 joint publications

Huihui Li

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

A Model Membrane Platform for Reconstituting Mitochondrial Membrane Dynamics

A Model Membrane Platform for Reconstituting Mitochondrial Membrane Dynamics

Published on : Sep 02, 2020

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

A Model Membrane Platform for Reconstituting Mitochondrial Membrane Dynamics

A Model Membrane Platform for Reconstituting Mitochondrial Membrane Dynamics

Published on : Sep 02, 2020

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos